Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 601–700 of 1,687
Ramassamy, C., Averill, D., Beffert, U., Bastianetto, S., Theroux, L., Lussier-Cacan, S., Cohn, J. S., Christen, Y., Davignon, J., Quirion, R., et al. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00102-1 · Cited by 241
“Studies from many research teams showed that the frequency of the «4 allele of APOE is markedly increased in AD [3–5].”
BackgroundApolipoprotein E and alzheimer's disease: Ethnic variation in genotypic risks
Maestre, G., Ottman, R., Stern, Y., Gurland, B., Chun, M., Tang, M., Shelanski, M., Tycko, B., & Mayeux, R. (1995) · Annals of Neurology · doi:10.1002/ana.410370217 · Cited by 243
Wragg, M., Talbot, C., Hutton, M., & Goate, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91140-x · Cited by 242
Jiang, X., Xu, K., Hoberman, J., Tian, F., Marko, A. J., Waheed, J. F., Harris, C. R., Marini, A. M., Enoch, M.-A., & Lipsky, R. H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300703 · Cited by 244
“Functional candidate gene studies have successfully identified genes involved in several neuropsychiatric traits and disorders including Alzheimer’s disease, Apo E (Corder et al, 1993); schizophrenia, COMT (Egan et al, 2001); and Parkinson’s disease (Toda et al, 2003).”
BackgroundMichikawa, M., Fan, Q., Isobe, I., & Yanagisawa, K. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741008.x · Cited by 244
“The finding that possession of the apoE gene allele,e4, is associated with an increased risk of developing Alzheimer’s disease (AD) (Corder et al., 1993; Poirier et al., 1993; Saunders et al., 1993; Strittmater et al., 1993) has highlighted the role of apoE in the CNS, and great attention has been…”
BackgroundThe Role of Drug Transporters at the Blood-Brain Barrier
de Boer, A. G., van der Sandt, I. C. J., & Gaillard, P. J. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140204 · Cited by 238
Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., & Hartmann, T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01679.2002 · Cited by 242
“Carriers of the ApoE4 allele of apolipoprotein E are predisposed to an earlier onset for developing AD (Corder et al., 1993), and a high cholesterol diet accelerates A deposition in transgenic mice (Refolo et al., 2000).”
BackgroundPathogenesis of Alzheimer's disease.
Swerdlow, R. H. (2007) · PubMed Central · Cited by 329
Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., Walhovd, K. B., & Initiative, F. T. A. D. N. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5506-12.2013 · Cited by 232
“The biomarker-defined group (n 37) consisted of participants with normal levels of baseline CSF amyloid- 1–42 based on an established criterion from the ADNI (i.e., 192 pg/ml; Shaw et al., 2009) who were negative for apolipoprotein 4 (Corder et al., 1993).”
MethodNovel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609896113 · Cited by 242
“The APOE4 allele is significantly overrepresented in lateonset AD patients and has a dosage effect on the risk and age of onset of AD (5), whereas APOE2 is protective against AD (6).”
BackgroundSporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 242
“It is now well established that possession of at least one APOE- 4 is a risk factor for both CAA and AD [17, 119, 152].”
BackgroundHuang, Y., Weisgraber, K. H., Mucke, L., & Mahley, R. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:189 · Cited by 242
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 241
Entorhinal Cortex β-Amyloid Load in Individuals with Mild Cognitive Impairment
Mufson, E. J., Chen, E.-Y., Cochran, E. J., Beckett, L. A., Bennett, D. A., & Kordower, J. H. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7086 · Cited by 237
Age effects on atrophy rates of entorhinal cortex and hippocampus
Du, A.-T., Schuff, N., Chao, L. L., Kornak, J., Jagust, W. J., Kramer, J. H., Reed, B. R., Miller, B. L., Norman, D., Chui, H. C., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.021 · Cited by 225
“The apolipoprotein E (APOE) 4 allele is a genetic risk factor for AD and vascular dementia [7,18].”
BackgroundThe Role of Sex and Sex Hormones in Neurodegenerative Diseases
Vegeto, E., Villa, A., Della Torre, S., Crippa, V., Rusmini, P., Cristofani, R., Galbiati, M., Maggi, A., & Poletti, A. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz005 · Cited by 232
Enrichr-KG: bridging enrichment analysis across multiple libraries
Evangelista, J. E., Xie, Z., Marino, G. B., Nguyen, N., Clarke, D. J. B., & Ma’ayan, A. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad393 · Cited by 233
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J.-Z. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 199
“Additionally, APOE4 carriers have an earlier age of onset, who show AD symptoms at around 75 or 65 years of age, compared to the average onset age of 84 years [67, 68].”
BackgroundFrom QTL to gene: the harvest begins
Korstanje, R., & Paigen, B. (2002) · Nature Genetics · doi:10.1038/ng0702-235 · Cited by 242
Hypertension is a potential risk factor for vascular dementia: systematic review
Sharp, S. I., Aarsland, D., Day, S., Sønnesyn, H., Alzheimer's Society Vascular Dementia Systematic Review Group, & Ballard, C. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2572 · Cited by 241
“Importantly, the APOE-e4 allele, known to confer increased risk for AD (Corder et al., 1993; Strittmatter et al., 1993), has been identified as a risk factor for incident dementia over long-term follow-up after stroke (Ballard et al., 2004; Del et al., 2005).”
BackgroundCataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241
“It is relevant, in this regard, that another major genetic risk factor for AD, the ApoE4 allele, also accelerates the onset of endosome pathology in AD (Corder et al., 1993).”
APOE Genotype Effects on Alzheimer's Disease Onset and Epidemiology
Ashford, J. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:157 · Cited by 235
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study
Dufouil, C., Richard, F., Fiévet, N., Dartigues, J. F., Ritchie, K., Tzourio, C., Amouyel, P., & Alpérovitch, A. (2005) · Neurology · doi:10.1212/01.wnl.0000160114.42643.31 · Cited by 228
Brown, B. M., Peiffer, J. J., & Martins, R. N. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.162 · Cited by 228
“91 The effect of the Apolipoprotein E ε 4 allele The Apolipoprotein E (APOE, gene) ε 4 allele is the strongest genetic risk factor for late onset AD.”
InfluentialStatins for the treatment of dementia
McGuinness, B., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub3 · Cited by 216
Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
Ingelman‐Sundberg, M. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00879.x · Cited by 242
Apolipoprotein E genotyping in Alzheimer's disease
National Institute on Aging/Alzheimer's Association Working Group, & Relkin, N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90284-6 · Cited by 241
Mosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
“0] and 68% accuracy for P-Tau/Aβ42 [χ(2)(1) = 4.”
BackgroundMethodInfluentialCase–control association mapping by proxy using family history of disease
Liu, J. Z., Erlich, Y., & Pickrell, J. K. (2017) · Nature Genetics · doi:10.1038/ng.3766 · Cited by 238
Elevated Low-Density Lipoprotein in Alzheimer's Disease Correlates with Brain Aβ 1–42 Levels
Kuo, Y.-M., Emmerling, M. R., Bisgaier, C. L., Essenburg, A. D., Lampert, H. C., Drumm, D., & Roher, A. E. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9652 · Cited by 238
Relationship of Apolipoprotein E and Age at Onset to Parkinson Disease Neuropathology
Ghebremedhin, E., Tredici, K. D., Vuksic, M., Rüb, U., Thal, D. R., Burbach, G. J., Rosenberger, A., Bickeböller, H., Deller, T., de Vos, R. A. I., et al. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000199572.96472.1c · Cited by 238
Beach, T. G., Wilson, J. R., Sue, L. I., Newell, A., Poston, M., Cisneros, R., Pandya, Y., Esh, C., Connor, D. J., Sabbagh, M., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0136-y · Cited by 233
“This situation remained stable until the discovery of the association between the apoE4 allele and AD [11, 45, 64] led to renewed interest in the vascular hypothe-”
BackgroundNeurogenesis in aging and age-related neurodegenerative diseases
Culig, L., Chu, X., & Bohr, V. A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101636 · Cited by 218
Astrocytes and Microglia Respond to Estrogen with Increased apoE mRNAin Vivoandin Vitro
Stone, D. J., Rozovsky, I., Morgan, T. E., Anderson, C. P., Hajian, H., & Finch, C. E. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6360 · Cited by 237
Glutathione S-transferase omega-1 modifiesage-at-onset of Alzheimer disease and Parkinson disease
Li, Y.-J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg357 · Cited by 234
“Since APOE, particularly the APOE-4 allele, is associated with age-at-onset in AD (1), and more recently in PD (33), we also perform association analysis by incorporating the number of APOE-4 alleles as a covariate.”
BackgroundMethodCorneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Wierenga, C. E., Hays, C. C., & Zlatar, Z. Z. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-141467 · Cited by 224
“Possessing the apolipoprotein E (APOE) epsilon4 ( 4) allele has been shown to increase AD risk by 3-8 fold and to considerably lower the age of disease onset [32].”
Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease
Martins, I. J., Berger, T., Sharman, M. J., Verdile, G., Fuller, S. J., & Martins, R. N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06408.x · Cited by 232
Elevation of serum copper levels in Alzheimer’s disease
Squitti, R., Lupoi, D., Pasqualetti, P., Dal Forno, G., Vernieri, F., Chiovenda, P., Rossi, L., Cortesi, M., Cassetta, E., & Rossini, P. M. (2002) · Neurology · doi:10.1212/wnl.59.8.1153 · Cited by 239
Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease
Jeong, S. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0096 · Cited by 233
“One major genetic risk factor for LO-SAD is the 4 allele of the apolipoprotein E gene (APOE4), which plays a crucial role in regulating cholesterol metabolism (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundiPS cell technologies: significance and applications to CNS regeneration and disease
Okano, H., & Yamanaka, S. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-22 · Cited by 233
Stone, D. J., Rozovsky, I., Morgan, T. E., Anderson, C. P., & Finch, C. E. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03180.1998 · Cited by 237
“The apoE e4 allele is a risk factor for AD (Corder et al., 1993; Poirier et al., 1993b), and AD patients with the e4 allele have less neuronal remodeling than those without the e4 allele (Arendt et al.”
BackgroundBrown, B. M., Peiffer, J. J., Taddei, K., Lui, J. K., Laws, S. M., Gupta, V. B., Taddei, T., Ward, V. K., Rodrigues, M. A., Burnham, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.107 · Cited by 235
Bondi, M. W., Salmon, D. P., Galasko, D., Thomas, R. G., & Thal, L. J. (1999) · Psychology and Aging · doi:10.1037//0882-7974.14.2.295 · Cited by 235
Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores
Leonenko, G., Baker, E., Stevenson-Hoare, J., Sierksma, A., Fiers, M., Williams, J., de Strooper, B., & Escott-Price, V. (2021) · Nature Communications · doi:10.1038/s41467-021-24082-z · Cited by 227
Structural models of human apolipoprotein A-I: a critical analysis and review
Brouillette, C. G., Anantharamaiah, G. M., Engler, J. A., & Borhani, D. W. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(01)00081-6 · Cited by 232
The Development of Amyloid β Protein Deposits in the Aged Brain
Thal, D. R., Capetillo-Zarate, E., Del Tredici, K., & Braak, H. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.6.re1 · Cited by 234
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans
Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.033 · Cited by 234
“Carriers of the ⑀4 allele of the ApoE (apolipoprotein E) gene, a commonly carried risk gene for late-onset AD (Roses and Saunders, 1994; Saunders et al., 1993), showed faster atrophic rates in the temporal lobes overall.”
BackgroundChang, M., Jonsson, P. V., Snaedal, J., Bjornsson, S., Saczynski, J. S., Aspelund, T., Eiriksdottir, G., Jonsdottir, M. K., Lopez, O. L., Harris, T. B., et al. (2010) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glq152 · Cited by 212
Insulin regulates astrocyte gliotransmission and modulates behavior
Cai, W., Xue, C., Sakaguchi, M., Konishi, M., Shirazian, A., Ferris, H. A., Li, M. E., Yu, R., Kleinridders, A., Pothos, E. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99366 · Cited by 226
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233
Berendsen, A. M., Kang, J. H., Feskens, E. J. M., de Groot, C. P. G. M., Grodstein, F., & van de Rest, O. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-017-0909-0 · Cited by 221
“Besides lifestyle factors, the apolipoprotein E ε4 (ApoE ε4) allele has been shown to be a major genetic risk factor for more rapid cognitive decline and earlier onset of Alzheimer’s Disease (AD) (11, 12).”
Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease
Matsuda, H. (2001) · Annals of Nuclear Medicine · doi:10.1007/bf02988596 · Cited by 232
Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
Marzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., Poschmann, J., Moore, K., Troakes, C., Al-Sarraj, S., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0253-7 · Cited by 232
Kelleher, R. J., & Soiza, R. L. (2013) · Europe PMC (PubMed Central) · Cited by 277
Regulation of cholesterol homeostasis
Goedeke, L., & Fernández-Hernando, C. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0857-5 · Cited by 213
“Indeed, the e4 allele of the ApoE gene was identified as the strongest genetic risk factor for AD [48, 49].”
BackgroundKanemitsu, H., Tomiyama, T., & Mori, H. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00898-x · Cited by 228
Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Raiha, I., Sourander, L., Winblad, B., & Blennow, K. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.298 · Cited by 227
Apolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms
Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231
Dementia, stroke, and vascular risk factors; a review
Sahathevan, R., Brodtmann, A., & Donnan, G. A. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00731.x · Cited by 230
Beta‐amyloid deposition and the aging brain
Rodrigue, K. M., Kennedy, K. M., & Park, D. C. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9118-x · Cited by 230
“…Deposition Risk There is a large literature on the risk conveyed by carrying the APOE-ε4 allele for age-related decline in cognitive function in both normal adults and AD patients and this is the best characterized genetic polymorphism associated with AD (Corder et al. 1993; Farrer et al. 1997).”
BackgroundGenetic and Lifestyle Predictors of 15‐Year Longitudinal Change in Episodic Memory
Josefsson, M., de Luna, X., Pudas, S., Nilsson, L., & Nyberg, L. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12000 · Cited by 211
“To the degree that accelerated episodic memory decline, as identified here, relates to forthcoming dementia, the higher proportion of e4 carriers may reflect the role of APOE e4 as a genetic risk factor for Alzheimer’s disease.(29) Some characteristics (subjective well-being, KIBRA, BDNF) did not predict group status.”
BackgroundDioguardi, M., Crincoli, V., Laino, L., Alovisi, M., Sovereto, D., Mastrangelo, F., Lo Russo, L., & Lo Muzio, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020495 · Cited by 212
“Moreover, it should be noted that the presence of this gene is associated with a greater risk in developing periodontitis [56].”
BackgroundAllelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
Artiga, M. J., Bullido, M. J., Sastre, I., Recuero, M., Garcı́a, M. A., Aldudo, J., Vázquez, J., & Valdivieso, F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01543-3 · Cited by 229
Mechanisms for cellular cholesterol transport: Defects and human disease
Ikonen, E. (2006) · Physiological Reviews · doi:10.1152/physrev.00022.2005 · Cited by 229
“Initially, a link between cholesterol and AD was established by the finding that the allele 4 of apoE predisposes to an early onset of AD (45).”
BackgroundArtificial gravity as a countermeasure in long-duration space flight
Lackner, J. R., & DiZio, P. A. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20001015)62:2<169::aid-jnr2>3.0.co;2-b · Cited by 42
The ups and downs of Wnt signaling in prevalent neurological disorders
De Ferrari, G. V., & Moon, R. T. (2006) · Oncogene · doi:10.1038/sj.onc.1210064 · Cited by 222
“Inheritance of the APOE-e4 allele is a risk factor for AD, including both the sporadic and late-onset familial forms of the disease (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993).”
BackgroundDaigle, I., & Li, C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12045 · Cited by 222
Kawahara, M., & Kuroda, Y. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00370-1 · Cited by 224
Hodges, J. R. (2006) · Brain · doi:10.1093/brain/awl275 · Cited by 212
“Perhaps the most significant discovery, in terms of overall impact to the burden of disease in the elderly, was the finding of association between gene dose of the apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset familial and sporadic cases (Corder et al., 1993; Strittmatter et al., 199…”
BackgroundCholesterol homeostasis in neurons and glial cells
Vance, J. E., Hayashi, H., & Karten, B. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.01.005 · Cited by 224
Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226
Microglia and Astrocytes in Disease: Dynamic Duo or Partners in Crime?
Liddelow, S. A., Marsh, S. E., & Stevens, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.07.006 · Cited by 226
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226
Impaired Glutathione Synthesis in Neurodegeneration
Aoyama, K., & Nakaki, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021021 · Cited by 226
“Apo E ε4 has been known as a risk factor for AD [132].”
BackgroundHolstege, H., Hulsman, M., Charbonnier, C., Grenier-Boley, B., Quenez, O., Grozeva, D., van Rooij, J. G. J., Sims, R., Ahmad, S., Amin, N., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01208-7 · Cited by 226
Self-citationFagan, A. M., Bu, G., Sun, Y., Daugherty, A., & Holtzman, D. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.47.30121 · Cited by 226
Protection against Alzheimer's disease with apoE ∈2
Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J., & Goate, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92557-7 · Cited by 225
APOE genotype alters glial activation and loss of synaptic markers in mice
Zhu, Y., Nwabuisi‐Heath, E., Dumanis, S. B., Tai, L. M., Yu, C., Rebeck, G. W., & Ladu, M. J. (2012) · Glia · doi:10.1002/glia.22289 · Cited by 224
“The APOE-e4 allele reduces the age of onset of AD (Corder et al., 1993), such that the great majority of individuals who develop Alzheimer’s disease in their 60s are APOE4 positive (Rebeck et al., 1994).”
BackgroundLing, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
The Non-Amyloidogenic Pathway: Structure and Function of α-Secretases
Kojro, E., & Fahrenholz, F. (2006) · Subcellular Biochemistry · doi:10.1007/0-387-23226-5_5 · Cited by 213
Bone mineral density, adiposity, and cognitive functions
Sohrabi, H. R., Bates, K. A., Weinborn, M., Bucks, R. S., Rainey-Smith, S. R., Rodrigues, M. A., Bird, S. M., Brown, B. M., Beilby, J., Howard, M., et al. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00016 · Cited by 222
Lipnicki, D. M., Crawford, J. D., Dutta, R., Thalamuthu, A., Kochan, N. A., Andrews, G., Lima-Costa, M. F., Castro-Costa, E., Brayne, C., Matthews, F. E., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002261 · Cited by 212
“Such findings are not unexpected given that APOE 4 is a risk factor for AD [13] and for the transition from MCI to AD [14].”
BackgroundUntangling Genetic Risk for Alzheimer’s Disease
Pimenova, A. A., Raj, T., & Goate, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.014 · Cited by 223
“Two coding SNPs define six APOE genotypes – ε2/ε2, ε2/ε3, ε3/ε3, ε2/ε4, ε3/ε4, ε4/ε4 listed from lowest to highest risk for AD (72, 73) .”
Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers
Wong, M. W., Braidy, N., Poljak, A., Pickford, R., Thambisetty, M., & Sachdev, P. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.008 · Cited by 223
“The important evidence that implicates cholesterol in AD pathogenesis is that a genetic variant of apolipoprotein E (APOE), APOE ε4 (encoded by the APOE ε4 allele) is the highest genetic risk factor for late-onset AD [8].”
BackgroundBenefits from Dietary Polyphenols for Brain Aging and Alzheimer’s Disease
Rossi, L., Mazzitelli, S., Arciello, M., Capo, C. R., & Rotilio, G. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9696-7 · Cited by 215
“Another risk factor for the late onset of AD is the occurrence of the allele 4 of apolipoprotein E gene (ApoE4) [76], thought to be in part involved in the processing of APP thereby contributing to Ab formation in ApoE4 carriers.”
BackgroundApolipoprotein E receptors: linking brain development and alzheimer's disease
Herz, J., & Beffert, U. (2000) · Nature Reviews Neuroscience · doi:10.1038/35036221 · Cited by 219
“In 1993, Allen Roses and colleagues discovered that carriers of the e4 isoform of ApoE are at greater risk of developing late-onset A”
BackgroundLaws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
“…apparent gene dosage effect, according to the number of APOE e4 alleles, in both familial (Corder et al. 1993) and sporadic (Frisoni et al. 1995) AD; the risk increases from 20% when no APOE e4 alleles are present to 90% when two copies of the APOE e4 allele are present (Corder et al. 1993).”
BackgroundResultInfluentialGlial activation in Alzheimer's disease: the role of Aβ and its associated proteins
Meda, L. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00307-4 · Cited by 222
Regulation of Amyloid Precursor Protein Cleavage
Mills, J., & Reiner, P. B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720443.x · Cited by 221
“, Marambaud P., Ancolio K., Buxbaum J. D., Khorkova O., Heroux J., Sahasrabudhe S., Martinez J., Warter J. M., Mohr M., and Checler F. (1997) Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid b peptides: their use to examine the cell biology of presenilins and the immunohisto…”
BackgroundInfluentialLifespan brain activity, β-amyloid, and Alzheimer's disease
Jagust, W. J., & Mormino, E. C. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.09.004 · Cited by 221
“The APOE4 allele has a dose-dependent effect on risk for AD and decreases the age of AD onset by more than 10 years [20].”
BackgroundOxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221
Genetics of Alzheimer’s Disease
Chouraki, V., & Seshadri, S. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00005-6 · Cited by 209
Christensen, H., Mackinnon, A. J., Korten, A. E., Jorm, A. F., Henderson, A. S., Jacomb, P., & Rodgers, B. (1999) · Psychology and Aging · doi:10.1037//0882-7974.14.3.365 · Cited by 207
Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease
Soldan, A., Pettigrew, C., Cai, Q., Wang, J., Wang, M.-C., Moghekar, A., Miller, M. I., & Albert, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.002 · Cited by 205
“APOE Genetic Analysis APOE ε4 genetic status, the main genetic risk factor for AD (Corder et al., 1993), was established in all but one of the participants (n=348).”
BackgroundInfluentialPlasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220
Blennow, K., Bogdanovic, N., Alafuzoff, I., Ekman, R., & Davidsson, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01273157 · Cited by 206
“, 1991), and an increased frequency of the ApoE4 allele is found in both familial and sporadic AD (Corder et al., 1993; Poirier et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993).”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213
“The age of onset of AD was also decreased in carriers of ApoE4 alleles [44] by 5–7 years per allele (i.”
Background
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.